Selective targeting of mutant huntingtin intron 1 improves rescue provided by antisense oligonucleotides in Huntington’s disease mice
Science Translational Medicine · 18.03.2026 · 18 (841)
DOI: 10.1126/scitranslmed.adv0702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 18.03.2026. Verfasst von Robert M Bragg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Washington, Seattle, WA 98104, USA. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Huntingtin Protein, Huntington Disease, Introns. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: CHDI Foundation, Wave Life Sciences.
Abstract (Originalsprache)
Huntington’s disease (HD) arises from the toxic gain of function caused by a CAG expansion in the coding region of the huntingtin ( HTT ) gene. HD is increasingly appreciated to emerge from multiple pathogenic processes, including somatic instability in mutant HTT ’s ( mHTT ) CAG repeat tract, which leads to diverse deleterious consequences. These include the alternative processing of HTT pre-mRNA to generate the HTT1a transcript that encodes the very toxic mHTT isoform referred to as HTT1a. We set out to compare the efficacy and safety of allele-selective lowering of mHTT with those of non–allele-selective lowering using antisense oligonucleotides (ASOs) in heterozygous Htt Q111 (Q111) mice. We developed a mutant-specific ASO (MutASO) targeting Htt intron 1 that selectively reduced mutant full-length HTT, as well as HTT1a, in the brains of Q111 mice. Compared with the rescue provided by a panallele-targeting ASO (PanASO) that lowers wild-type HTT and full-length mHTT (sparing HTT1a), the MutASO essentially eliminated aggregate formation and provided marked protection from transcriptional dysregulation in HD knockin mice. Thus, by targeting the ASO to the region upstream of the cryptic polyadenylation sites required to generate the HTT1a transcript, our allele-selective MutASO potently reduced HTT1a transcript and protein levels. Our findings suggest that HTT1a may have a disproportionate impact on aggregate formation and transcriptional dysregulation and that lowering the levels of HTT1a could provide benefit when designing HTT-lowering–based therapeutic strategies for HD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Washington, Seattle, WA 98104, USA.
- Huntington's Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
ORCID-Profile: Robert M Bragg, Christian Landles, Edward J Smith, Georgina F Osborne, Ella W Mathews, Jeffrey P Cantle, Gillian P Bates, Jeffrey B Carroll
Förderung
- CHDI Foundation
- Wave Life Sciences
Zitieren
APA
Bragg, R. M., Landles, C., Smith, E. J., Osborne, G. F., Mathews, E. W., Cantle, J. P., Bates, G. P., & Carroll, J. B. (2026). Selective targeting of mutant huntingtin intron 1 improves rescue provided by antisense oligonucleotides in Huntington’s disease mice. Science Translational Medicine, 18(841). https://doi.org/10.1126/scitranslmed.adv0702
Vancouver
Bragg RM, Landles C, Smith EJ, Osborne GF, Mathews EW, Cantle JP, et al. Selective targeting of mutant huntingtin intron 1 improves rescue provided by antisense oligonucleotides in Huntington’s disease mice. Science Translational Medicine. 2026;18(841). doi:10.1126/scitranslmed.adv0702
BibTeX
@article{Bragg2026,
author = {Bragg, Robert M and Landles, Christian and Smith, Edward J and Osborne, Georgina F and Mathews, Ella W and Cantle, Jeffrey P and Bates, Gillian P and Carroll, Jeffrey B},
title = {Selective targeting of mutant huntingtin intron 1 improves rescue provided by antisense oligonucleotides in Huntington’s disease mice},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {841},
doi = {10.1126/scitranslmed.adv0702}
}
EUVIMED